The application progress of amyloid protein PET-CT in the diagnosis and treatment evaluation of Alzheimer's disease

Xifen GONG, Xiaofeng LI

Chinese Journal of Alzheimer's Disease and Related Disorders ›› 2026, Vol. 9 ›› Issue (5) : 357-361.

PDF(804 KB)
Home Journals Chinese Journal of Alzheimer's Disease and Related Disorders
Chinese Journal of Alzheimer's Disease and Related Disorders

Abbreviation (ISO4): Chinese Journal of Alzheimer's Disease and Related Disorders      Editor in chief: Jun WANG

About  /  Aim & scope  /  Editorial board  /  Indexed  /  Contact  / 
PDF(804 KB)
Chinese Journal of Alzheimer's Disease and Related Disorders ›› 2026, Vol. 9 ›› Issue (5) : 357-361. DOI: 10.3969/j.issn.2096-5516.2026.05.012
Reviews

The application progress of amyloid protein PET-CT in the diagnosis and treatment evaluation of Alzheimer's disease

Author information +
History +

Abstract

Alzheimer's disease (AD) is a common neurodegenerative disorder characterized pathologically by the deposition of senile plaques and neurofibrillary tangles, with biochemical alterations involving abnormal accumulation of β-amyloid (Aβ) and hyperphosphorylation of TAU protein in the brain. As an advanced molecular imaging technique, positron emission tomography-computed tomography (PET-CT) enables non-invasive, high-resolution visualization of the spatiotemporal distribution patterns of Aβ deposition. This review summarizes the current applications of amyloid PET-CT in the diagnosis and treatment of AD, including its capability for early detection of Aβ deposition, dynamic tracking of spatiotemporal Aβ changes, comparison with other diagnostic methods, correlation with Tau PET-CT findings, role in therapeutic evaluation, as well as its limitations and future prospects, aiming to provide direction for clinical management and research in AD.

Key words

PET-CT / Alzheimer's disease / Amyloid beta protein / Diagnosis / Treatment

Cite this article

Download Citations
Xifen GONG , Xiaofeng LI. The application progress of amyloid protein PET-CT in the diagnosis and treatment evaluation of Alzheimer's disease[J]. Chinese Journal of Alzheimer's Disease and Related Disorders. 2026, 9(5): 357-361 https://doi.org/10.3969/j.issn.2096-5516.2026.05.012

References

[1]
Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer’s disease[J]. Lancet (London, England), 2021, 397(10284): 1577-1590.
[2]
Zhao Q, Du X, Chen W, et al. Advances in diagnosing mild cognitive impairment and Alzheimer’s disease using 11C-PIB- PET/CT and common neuropsychological tests[J]. Front Neuroscie, 2023, 17: 1216215.
[3]
Zhang Y, Chen H, Li R, et al. Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future[J]. Signal Transduct Target Ther, 2023, 8(1): 248.
[4]
Clark C M, Pontecorvo M J, Beach T G, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: A prospective cohort study[J]. Lancet Neurol, 2012, 11(8): 669-678.
[5]
Ossenkoppele R, Rabinovici GD, Smith R, et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders[J]. JAMA, 2018, 320(11):1151-1162.
[6]
Kim C M, Montal V, Diez I, et al. Network interdigitations of Tau and amyloid-beta deposits define cognitive levels in aging[J]. Hum Brain Mapp. 2021, 42(10):2990-3004.
[7]
Michalowska M M, Herholz K, Hinz R, et al. Evaluation of in vivo staging of amyloid deposition in cognitively unimpaired elderly aged 78-94[J]. Mol Psychiatry, 2022, 27(10):4335-4342.
[8]
Menon V. 20 years of the default mode network: A review and synthesis[J]. Neuron, 2023, 111(16): 2469-2487.
[9]
Cui L, Zhang Z, Tu Y Y, et al. Association of precuneus Aβ burden with default mode network function[J]. Alzheimers Dement, 2025, 21(1): e14380.
[10]
Nedergaard M, Goldman S A. Glymphatic failure as a final common pathway to dementia[J]. Science, 2020, 370(6512): 50-56.
[11]
Chapleau M, La Joie R, Yong K, et al. Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis[J]. Lancet Neurol, 2024, 23(2): 168-177.
[12]
Doré V, Villemagne V L, Bourgeat P, et al. Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease[J]. JAMA neurology, 2013, 70(7): 903-911.
[13]
Villemagne V L, Burnham S, Bourgeat P, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: A prospective cohort study[J]. Lancet Neurol, 2013, 12(4): 357-367.
[14]
Villain N, Chételat G, Grassiot B, et al. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer’s disease: A voxelwise PiB-PET longitudinal study[J]. Brain, 2012, 135(Pt 7): 2126-2139.
[15]
Jack C R, Wiste H J, Vemuri P, et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease[J]. Brain, 2010, 133(11): 3336-3348.
[16]
Xu C, Xu E, Xiao Y, et al. A multiscale model to explain the spatiotemporal progression of amyloid beta and tau pathology in Alzheimer’s disease[J]. Int J Biol Macromol, 2025, 310(Pt 2): 142887.
[17]
Jack C R, Knopman D S, Jagust W J, et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade[J]. Lancet Neurol, 2010, 9(1): 119-128.
[18]
Ossenkoppele R, Van Der Kant R, Hansson O. Tau biomarkers in Alzheimer’s disease: Towards implementation in clinical practice and trials[J]. Lancet Neurol, 2022, 21(8): 726-734.
[19]
Graff-Radford J, Yong K X X, Apostolova L G, et al. New insights into atypical Alzheimer’s disease in the era of biomarkers[J]. Lancet Neurol, 2021, 20(3): 222-234.
[20]
Frisoni G B, Hansson O, Nichols E, et al. New landscape of the diagnosis of Alzheimer’s disease[J]. Lancet, 2025, 406(10510): 1389-1407.
[21]
Leng F, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: Where do we go from here?[J]. Nat Rev Neurol, 2021, 17(3): 157-172.
[22]
Triumbari E K A, Chiaravalloti A, Schillaci O, et al. Positron emission tomography/computed tomography imaging in therapeutic clinical trials in Alzheimer’s disease: An overview of the current state of the art of research[J]. J Alzheimers Dis, 2024, 101(s1): S603-S628.
[23]
Graff-Radford J, Yong K X X, Apostolova L G, et al. New insights into atypical Alzheimer's disease in the era of biomarkers[J]. Lancet Neurol, 2021, 20(3):222-234.
[24]
Laforce R, Soucy J P, Sellami L, et al. Molecular imaging in dementia: Past, present, and future[J]. Alzheimers Dement, 2018, 14(11): 1522-1552.
[25]
Jack C R, Andrews J S, Beach T G, et al. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s association workgroup[J]. Alzheimers Dement, 2024, 20(8): 5143-5169.
[26]
Moon S, Kim S, Mankhong S, et al. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans[J]. Alzheimers Res Ther, 2021, 13(1):22.
[27]
Rabinovici G D, Gatsonis C, Apgar C, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia[J]. JAMA, 2019, 321(13): 1286-1294.
[28]
Salvadó G, Grothe M J, Groot C, et al. Differential associations of APOE-ε2 and APOE-ε4 alleles with PET-measured amyloid-β and tau deposition in older individuals without dementia[J]. Eur J Nucl Med Mol Imaging, 2021, 48(7): 2212-2224.
[29]
Insel PS, Hansson O, Mattsson-Carlgren N. Association Between Apolipoprotein E ε2 vs ε4, Age, and β-Amyloid in Adults Without Cognitive Impairment[J]. JAMA Neurol, 2021, 78(2):229-235.
[30]
Jeremic D, Jiménez-Díaz L, Navarro-López J D. Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer’s disease: A systematic review[J]. Ageing Res Rev, 2021, 72: 101496.
[31]
Yadollahikhales G, Rojas J C. Anti-Amyloid immunotherapies for Alzheimer’s disease: A 2023 clinical update[J]. Neurotherapeutics, 2023, 20(4): 914-931.
[32]
Kang C. Donanemab: First approval[J]. Drugs, 2024, 84(10): 1313-1318.
[33]
Sims J R, Zimmer J A, Evans C D, et al. Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial[J]. JAMA, 2023, 330(6): 512-527.
[34]
Van Dyck C H, Swanson C J, Aisen P, et al. Lecanemab in early Alzheimer's disease[J]. N Engl J Med, 2023, 388(1):9-21.
[35]
Strobel J, Yousefzadeh-Nowshahr E, Deininger K, et al. Exploratory tau PET/CT with [11C]PBB3 in patients with suspected Alzheimer’s disease and frontotemporal lobar degeneration: A pilot study on correlation with PET imaging and cerebrospinal fluid biomarkers[J]. Biomedicines, 2024, 12(7): 1460.

Footnotes

利益冲突声明 所有作者在本研究中均不存在利益冲突。

PDF(804 KB)

Accesses

Citation

Detail

Sections
Recommended

/

〈 〉